The function and efficacy of Pralsetinib
Pralsetinib is a highly selective RET inhibitor that exerts anti-tumor effects by targeting and inhibiting RET gene fusion and mutation, blocking downstream signaling pathways. It is mainly used to treat solid tumors such as RET positive non-small cell lung cancer and thyroid cancer.
1. Pharmacological effects
(1) Pratinib selectively inhibits abnormal activation of RET protein, blocks signaling pathways such as MAPK and PI3K-AKT, inhibits tumor cell proliferation, and induces apoptosis.
(2) This drug has high selectivity for RET gene fusion (such as KIF5B-RET, CCDC6-RET) and activation mutations (such as RET V804L/M, M918T).
2. Main benefits
(1) Non small cell lung cancer: Used to treat adult patients with metastatic RET fusion positive non-small cell lung cancer, designated as an orphan drug by the FDA.
(2) Thyroid cancer: Used for advanced or metastatic RET fusion positive thyroid cancer in patients aged 12 years and above, especially in cases of radiation iodine refractory.
3. Clinical advantages
(1) Oral administration is convenient, with high selectivity and potent inhibitory effects, and can accurately target RET variant tumors.
(2) This provides a new treatment option for RET positive patients who have failed traditional treatments, significantly improving their prognosis.
Disclaimer：《The function and efficacy of Pralsetinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！